Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ridvan Arda Demirci
Observed name:
Ridvan A. Demirci
Institutions:
University of Iowa,
University of Washington,
University of Iowa Health Care
Observed institutions:
University of Iowa,
University of Washington,
University of Iowa Health Care
ORCID:
0009-0005-9123-4105
Observed ORCID:
0009-0005-9123-4105
OpenAlex ID:
A5102610291
PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received177Lu-PSMA-617: Importance of18F-FDG–Avid Discordant Findings
2024
·
Ridvan Arda Demirci
, Alireza Ghodsi
, et al.
·
Journal of Nuclear Medicine
·
28
PDF
SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving177Lu-PSMA-617
2024
·
Ridvan Arda Demirci
, Roman Gulati
, et al.
·
Journal of Nuclear Medicine
·
25
PDF
Hematologic toxicity in 177lu-PSMA-617 treatment for mCRPC: Unraveling the impact of PSMA PET bone tumor volume (PSMA-bTTV).
2024
·
Alireza Ghodsi
, Ridvan Arda Demirci
, et al.
·
Journal of Clinical Oncology
·
7
PDF
PSMA PET/CT–derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177 Lu-PSMA-617
2026
·
Alireza Ghodsi
, Lukas Owens
, et al.
·
Radiology
·
6
The Role of SPECT/CT in 177Lu-PSMA-617 Theranostics: Case-based Review of Response and Progression Patterns
2025
·
Alireza Ghodsi
, Ridvan Arda Demirci
, et al.
·
Clinical Nuclear Medicine
·
4
Gene expression inference from cell-free DNA using uncertainty-aware deep learning
2026
·
Robert D. Patton
, A. Patrick McDeed
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
·
3
Prognostic Value of Cycle 1 SPECT SUV mean in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 177 Lu-PSMA-617
2026
·
Alireza Ghodsi
, Ridvan A. Demirci
, et al.
·
Journal of Nuclear Medicine
·
2
Association between SPECT/CT total tumor volume (TTV) and new lesions (NLs) in early cycles of 177Lu-PSMA-617 (LuPSMA) and progression-free and overall survival (PFS and OS) in men with metastatic castration-resistant prostate cancer (mCRPC).
2024
·
Ridvan Arda Demirci
, Roman Gulati
, et al.
·
Journal of Clinical Oncology
·
1
The EMERALD-3 Trial: STRIDE with or without Lenvatinib plus TACE for Embolization-eligible Hepatocellular Carcinoma
2026
·
Ridvan A. Demirci
, Gustavo H Andrade
·
Radiology Imaging Cancer
Prostate-specific Membrane Antigen PET/Computed Tomography in Prostate Cancer
2026
·
Ridvan A. Demirci
, Amir Iravani
·
Radiologic Clinics of North America
Outcomes of cabazitaxel following 177Lu-PSMA-617 (LuPSMA) in patients with metastatic castration-resistant prostate cancer (mCRPC).
2026
·
Candace Haghighi
, Ethan Lo
, et al.
·
Journal of Clinical Oncology
PDF
Feasibility and outcomes of response-adapted and retreatment 177 Lu-PSMA-617 therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).
2026
·
Alireza Ghodsi
, Ridvan A. Demirci
, et al.
·
Journal of Clinical Oncology
PDF
PSMA PET-guided Intensification of Salvage Radiotherapy after Radical Prostatectomy
2025
·
Ridvan A. Demirci
, Amir Iravani
·
Radiology Imaging Cancer
Posttreatment SPECT/CT as a Prognostic Tool in Patients Treated with 177Lu-PSMA-617
2025
·
Ridvan Arda Demirci
, Yusuf Menda
·
Radiology Imaging Cancer
Examining laboratory-based VISION eligibility and 177Lu-PSMA-617 outcomes in patients with metastatic castration-resistant prostate cancer.
2024
·
Alireza Ghodsi
, Ridvan Arda Demirci
, et al.
·
Journal of Clinical Oncology
Association between PET-based TheraP eligibility and 177Lu-PSMA-617 (LuPSMA) outcomes in VISION-eligible patients with metastatic castration-resistant prostate cancer (mCRPC).
2024
·
Ridvan Arda Demirci
, Roman Gulati
, et al.
·
Journal of Clinical Oncology
PDF
Show more works
View as search
Works count:
16
Citation count:
76
H-index:
4
I10-index:
2
Year
Topic
Type